Compare KB Financial Group, Inc. (KB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs 10X Genomics Inc — how do they compare? KB Financial Group, Inc. trades at $123.07 (market cap $42.62B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: KB Financial Group, Inc. is far larger — about 4.2× 10X Genomics Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and 10X Genomics Inc for 91 Days on average.
| KB | TXG | |
|---|---|---|
Market Cap | $42.62B | $10.07B |
Volume | 164,291 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $132.88 | $97.74 |
52-Week Low | $77.50 | $11.48 |
Typical Hold Time | 33 Days | 91 Days |
Enterprise Value | $215.53T | $9.59B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $123.07, down 1.33% today, with mixed technical signals showing a neutral overall trend. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.79 beating expectations of $3.51. Revenue growth has been steady from $17.8T in 2022 to $21.2T in 2025, with net income margins improving to 27.47%. Analyst sentiment is mixed with 33% buy ratings and 67% hold recommendations.
KB presents a compelling value opportunity with a P/E of 9.68 and P/B of 0.94 below industry averages. The main investment thesis centers on continued earnings momentum and South Korean market outperformance, though risks include banking sector volatility and interest rate sensitivity. The stock's current valuation discount to intrinsic value suggests potential upside if earnings growth persists.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
